Belimumab: all 76 studies that test it

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitizedRecruitingNCT07539857Phase 2
• The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentRecruitingNCT07340463Phase 2
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Effect of Belimumab on Antibody Titers in Primary APS PatientsRecruitingNCT06747312Phase 2
• A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)RecruitingNCT06716606Phase 3
• A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsRecruitingNCT06576271Phase 1
• A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue DiseaseRecruitingNCT06572384Phase 3
• Belimumab After Rituximab in Resistant Primary Juvenile SSRecruitingNCT06410833Phase 4
• Belimumab in Autoimmune HepatitisRecruitingNCT06381453Phase 2
• A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung DiseaseRecruitingNCT05878717Phase 2/3
• Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus NephritisRecruitingNCT05863936Phase 3
• A Model About the Response of Belimumab in SLENot yet recruitingNCT04893161Phase 4
• Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)RecruitingNCT04629144Phase 2
• Sequential Belimumab and T-cell Based Therapy in SLERecruitingNCT04447053Phase 4
• Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)RecruitingNCT04097561Phase 1
• Belimumab With Rituximab for Primary Membranous NephropathyRecruitingNCT03949855Phase 2
• A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus ErythematosusCompletedNCT05917288Phase 1Results posted
• Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)CompletedNCT04908865Phase 4Results posted
• Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple SclerosisTerminatedNCT04767698Phase 2Results posted
• Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT04179032Phase 2Results posted
• CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant RecipientsTerminatedNCT03591380Phase 2Results posted
• Belimumab Treatment of Emphysema Patients With Anti-GRP78 AutoantibodiesCompletedNCT03244059Phase 2Results posted
• Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell TransplantationCompletedNCT03207958Phase 1Results posted
• Belimumab Phase I Study in Chinese Subjects With Systemic Lupus ErythematosusCompletedNCT02880852Phase 1Results posted
• Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's SyndromeCompletedNCT02631538Phase 2Results posted
• Belimumab in Idiopathic Inflammatory MyositisCompletedNCT02347891Phase 2/3Results posted
• Rituximab and Belimumab for Lupus NephritisCompletedNCT02260934Phase 2Results posted
• Belimumab Treatment Holiday and Treatment Re-start Study in Lupus PatientsCompletedNCT02119156Phase 3Results posted
• Belimumab Assessment of Safety in SLECompletedNCT01705977Phase 4Results posted
• Belimumab for the Treatment of Diffuse Cutaneous Systemic SclerosisCompletedNCT01670565Phase 2Results posted
• Belimumab in Remission of VASculitisCompletedNCT01663623Phase 3Results posted
• Pediatric Lupus Trial of Belimumab Plus Background Standard TherapyCompletedNCT01649765Phase 2Results posted
• Efficacy and Safety of Belimumab in Patients With Active Lupus NephritisCompletedNCT01639339Phase 3Results posted
• Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT01632241Phase 4Results posted
• A Study of Belimumab in Idiopathic Membranous GlomerulonephropathyCompletedNCT01610492Phase 2Results posted
• BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115CompletedNCT01597622Phase 3Results posted
• A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01597492Phase 4Results posted
• Study of Belimumab Administered Subcutaneously to Healthy SubjectsCompletedNCT01583530Phase 1Results posted
• A Study of Belimumab in the Prevention of Kidney Transplant RejectionCompletedNCT01536379Phase 2Results posted
• A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01484496Phase 3Results posted
• The Evaluation of Belimumab in Myasthenia Gravis (MG)CompletedNCT01480596Phase 2Results posted
• GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast AsiaCompletedNCT01345253Phase 3Results posted
• Desensitization With Belimumab in Sensitized Patients Awaiting Kidney TransplantTerminatedNCT01025193Phase 2Results posted
• Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)TerminatedNCT00732940Phase 2Results posted
• A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United StatesCompletedNCT00724867Phase 3Results posted
• A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057CompletedNCT00712933Phase 3Results posted
• A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01TerminatedNCT00583557Phase 2Results posted
• A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02CompletedNCT00583362Phase 2Results posted
• A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00424476Phase 3Results posted
• A Study of Belimumab in Subjects With Systemic Lupus ErythematosusCompletedNCT00410384Phase 3Results posted
• A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)CompletedNCT00071812Phase 2Results posted
• Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00071487Phase 2Results posted
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)Active, not recruitingNCT06411249Phase 4
• Belimumab for Treatment of cGVHD Following Allo-HCTWithdrawnNCT05604742Phase 1/2
• Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus ErythematosusStatus unknownNCT05262686Phase 3
• Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum DisordersCompletedNCT05154734Phase 1/2
• Belimumab in Patients with Chronic Lymphocytic LeukemiaActive, not recruitingNCT05069051Phase 2
• The BeLimumab Antiphospholipid Syndrome Trial (BLAST)Status unknownNCT05020782Phase 2/3
• Belimumab In Early Systemic Lupus ErythematosusCompletedNCT04956484Phase 4
• Belimumab Treatment for IgG4-related DiseaseStatus unknownNCT04660565Phase 4
• A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2CompletedNCT04611971Phase 1
• Efficacy and Safety of Belimumab in SLE PatientsCompletedNCT04515719Phase 4
• Rituximab and Belimumab Combination Therapy in PR3 VasculitisStatus unknownNCT03967925Phase 2
• Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisActive, not recruitingNCT03844061Phase 2
• Synergetic B-cell Immunomodulation in SLE - 2nd Study.CompletedNCT03747159Phase 3
• Belimumab Impacting Transplant EligibilityCompletedNCT02500251Phase 1/2
• Synergetic B-cell Immodulation in SLECompletedNCT02284984Phase 2
• Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding PolypharmacyStatus unknownNCT02270970Phase 4
• A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy SubjectsCompletedNCT01894360Phase 1
• Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous NephropathyWithdrawnNCT01762852Phase 2
• A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.WithdrawnNCT01440361Phase 2
• Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT01381536Phase 1
• Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's SyndromeCompletedNCT01160666Phase 2
• A Study of Belimumab in Treating Symptomatic Waldenstroms MacroglobulinaemiaStatus unknownNCT01142011Phase 2
• Efficacy and Safety of Belimumab in Primary Sjögren's SyndromeCompletedNCT01008982Phase 2
• Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)CompletedNCT00657007Phase 1

← Belimumab overview